Nalmefene Hydrochloride Injection

DRUG2 trials

Sponsors

Purdue Pharma LP, Knoa Pharma LLC

Conditions

Opioid Overdose

Phase 1

Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

CompletedNCT07543276

Knoa Pharma LLCOpioid Overdose

Start: 2026-02-06End: 2026-04-03Updated: 2026-06-05

Phase 4

Clinical Outcomes From Nalmefene

WithdrawnNCT05808881

Purdue Pharma LPOpioid Overdose

Start: 2023-06-30End: 2024-05-31Updated: 2023-07-12